A phase 2 randomized, placebo-controlled crossover trial to evaluate safety and efficacy of platelet-rich plasma injections for Peyronie's disease: clinical trial update.

Autor: Ledesma BR; Desai Sethi Urology Institute, University of Miami, Miller School of Medicine, Miami, FL, USA., Velasquez DA; Desai Sethi Urology Institute, University of Miami, Miller School of Medicine, Miami, FL, USA., Egemba C; Desai Sethi Urology Institute, University of Miami, Miller School of Medicine, Miami, FL, USA., Molina M; Desai Sethi Urology Institute, University of Miami, Miller School of Medicine, Miami, FL, USA., Ibrahim E; Desai Sethi Urology Institute, University of Miami, Miller School of Medicine, Miami, FL, USA., Costantini-Mesquita F; Desai Sethi Urology Institute, University of Miami, Miller School of Medicine, Miami, FL, USA., Deebel NA; Department of Urology, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Han S; Biostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA., Reis IM; Biostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA.; Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA., Saltzman R; Desai Sethi Urology Institute, University of Miami, Miller School of Medicine, Miami, FL, USA., Ramasamy R; Desai Sethi Urology Institute, University of Miami, Miller School of Medicine, Miami, FL, USA. ramasamy@miami.edu.
Jazyk: angličtina
Zdroj: International journal of impotence research [Int J Impot Res] 2024 Feb 29. Date of Electronic Publication: 2024 Feb 29.
DOI: 10.1038/s41443-024-00844-3
Abstrakt: Peyronie's Disease (PD) is characterized by fibrotic plaques in the penile tunica albuginea, causing curvature and painful erections. Current treatments have limited established efficacy. Platelet-Rich Plasma (PRP), known for modulating inflammation, offers a potential alternative. This randomized, placebo-controlled, crossover study at the University of Miami assesses PRP's safety and efficacy for PD. Forty-one PD patients were randomized into PRP-placebo (Group A) and placebo-PRP (Group B) sequences, receiving two injections of each treatment over three months, with a crossover to receive two injections of alternate treatment over the next three months. Assessments include pain scale, goniometry, questionnaires, and curvature evaluations. Preliminary analysis of 28 patients shows that PRP is safe. There were no adverse events, including penile complications, during follow-up. Pain scores during treatments showed no significant difference between PRP and placebo (p = 0.52). Over six months, the PRP-Placebo group's median PDQ score decreased from 1.9 (IQR: 1.7-2.9) to 1.4 (IQR: 0.7-2.1). This change was not statistically significant (p = 0.098). In contrast, the Placebo-PRP group showed a significant reduction from 1.8 (IQR: 1.4-2.6) to 1.2 (IQR: 1.0-2.0) (p = 0.020). No significant changes in IIEF scores were observed. Both groups initially had a median penile curvature of 40 degrees. At 3 months, the PRP-Placebo group's curvature decreased to 38 degrees (IQR: 35-47.5), while the Placebo-PRP group decreased to 35 degrees (IQR: 30-60). At 6 months, the PRP-Placebo group showed a significant reduction to 25 degrees (IQR: 20-40, p = 0.047), while the Placebo-PRP group's reduction to 32.5 degrees (IQR: 20-50) was not significant (p = 0.490). These early results indicate a delayed PRP effect, prompting further investigation into its long-term impacts. Although limited by sample size, this study suggests PRP injections as a safe treatment for PD, with ongoing research aiming to clarify its therapeutic value.
(© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: